Opioid misuse and substance use disorders (SUDs) including opioid use disorder (OUD) are common and negatively impact quality of life. Hospice clinicians' experiences with these conditions have not been well described. We sought to explore hospice clinicians' knowledge, practices, and comfort caring for patients with opioid misuse (e.g., a pattern of unsanctioned opioid use escalation, or concurrent illicit substance use) and SUDs. We recruited hospice clinicians in the United States via national hospice and palliative care organizations to complete an online survey designed by the study authors and pilot tested with an interdisciplinary group of current/former hospice clinicians. One hundred seventy-five clinicians (40% nurses, 40% physicians, 16% nurse practitioners) responded to the survey; most had cared for two or more hospice patients with opioid misuse or SUD in the past month. The majority felt confident identifying opioid misuse (94%) and taking SUD histories (79%). Most (62%) felt it is their role to treat hospice patients for SUD, though 56% lacked comfort in using buprenorphine for OUD treatment. While the majority felt it is their role to treat pain in hospice patients with SUDs (94%) and that hospice can help patients with SUDs (94%), many were not comfortable managing pain in patients taking buprenorphine (45%) or naltrexone (49%) for SUDs. Most felt comfortable managing pain in patients taking methadone for SUD (73%). Opioid misuse and SUD are common in hospice. Though clinicians are comfortable taking relevant histories, they feel less comfortable managing patients' opioid misuse or SUD, or these patients' pain.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11074426 | PMC |
| http://dx.doi.org/10.1089/jpm.2023.0082 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
mHealth Incentivized Adherence Plus Patient Navigation (MIAPP): protocol for a pilot randomized controlled trial to improve linkage and retention on buprenorphine for hospitalized patients with methamphetamine use and opioid use disorder.
Addict Sci Clin Pract
January 2025
Department of Medicine, Division of General Internal Medicine, University of Washington/Harborview Medical Center, 325 9Th Avenue, Box 359780, Seattle, WA, 98104, USA.
Background: Initiation of buprenorphine for treatment of opioid use disorder (OUD) in acute care settings improves access and outcomes, however patients who use methamphetamine are less likely to link to ongoing treatment. We describe the intervention and design from a pilot randomized controlled trial of an intervention to increase linkage to and retention in outpatient buprenorphine services for patients with OUD and methamphetamine use who initiate buprenorphine in the hospital.
Methods: The study is a two-arm pilot randomized controlled trial (N = 40) comparing the mHealth Incentivized Adherence Plus Patient Navigation (MIAPP) intervention to treatment as usual.
A deep learning analysis for dual healthcare system users and risk of opioid use disorder.
Sci Rep
January 2025
Washington DC VA Medical Center, Washington, DC, USA.
The opioid crisis has disproportionately affected U.S. veterans, leading the Veterans Health Administration to implement opioid prescribing guidelines.
View Article and Find Full Text PDFAssessing Prevalence of Nonmedically Used Prescription Drug Involvement in Overdose Deaths Through Linkage of State Unintentional Drug Overdose Reporting System and Controlled Substances Monitoring Program Data.
Subst Use Misuse
January 2025
Tennessee Department of Health, Office of Informatics and Analytics, Nashville, TN, USA.
Background: While illicit substances are commonly involved in the overdose crisis, prescription substances still play a role. Oftentimes, decedents do not have prescriptions for these substances at the time of death. As such, we sought to examine the prevalence of nonmedical drug use in Tennessee through linkage of fatal drug overdose and prescription data.
View Article and Find Full Text PDFCan social pain be medicated away? A pilot study on everyday discrimination and its exacerbation of opioid misuse risk in people of color with chronic pain.
Health Psychol Behav Med
January 2025
Department of Psychology, University of Florida, Gainesville, FL, USA.
Despite mounting evidence of a robust relation between discrimination and poor pain outcomes in people of color (POC) with chronic pain, little is known about everyday discrimination's role in increasing the risk of opioid misuse and its potential interactive effects. This study aimed to evaluate the potential moderating effect of everyday discrimination on the relationship between chronic pain severity and the risk of opioid misuse among POC with chronic pain. Everyday discrimination was assessed using the 9-item Everyday Discrimination Scale (EDS), while the risk of opioid misuse was measured with the 14-item Screener and Opioid Assessment for Patients with Pain (SOAPP).
View Article and Find Full Text PDFCognitive control in individuals with heroin use disorder after prolonged methadone maintenance treatment.
BMC Psychiatry
January 2025
School of Mental Health, Bengbu Medical University, Bengbu, Anhui, 233030, China.
Background: Although impaired cognitive control is common during the acute detoxification phase of substance use disorders (SUD) and is considered a major cause of relapse, it remains unclear after prolonged methadone maintenance treatment (MMT). The aim of the present study was to elucidate cognitive control in individuals with heroin use disorder (HUD) after prolonged MMT and its association with previous relapse.
Methods: A total of 63 HUD subjects (41 subjects with previous relapse and 22 non-relapse subjects, mean MMT duration: 12.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!